Skip to Main Content
Our Commitment to Diversity
Michael R. Marks

Michael Marks is a patent technical specialist in the firm’s Boston office. He is a member of the IP Procurement and Portfolio Management practice group.

This is a temporary biography. A complete biography will be available soon.

Prior to joining the firm, Michael served as a doctoral candidate in the neurobiology department at the University of Pittsburgh. Michael has experience in immunocytochemistry, coding, mass spectrometry, RNA-sequencing, western blot analysis, rodent behavioral training, and molecular cloning, among other skills.

  • Fan P, DeChellis-Marks MR, Kofler JK, Sweet RA, Wang L. Efficacy Difference of Antipsychotics in Alzheimer’s Disease and Schizophrenia: Explained with Network Efficiency and Pathway Analysis Methods. Brief. Bioinformatics. 2022 Aug. 11.
  • DeChellis-Marks MR, Wei Y, Ding Y, Wolfe CM, Krivinko JM, MacDonald ML, Lopez OL, Sweet RA, Kofler J. Psychosis in Alzheimer's Disease Is Associated With Increased Excitatory Neuron Vulnerability and Post-transcriptional Mechanisms Altering Synaptic Protein Levels. Frontiers in Neurology. 2022;13. doi: 10. 3389/fneur.2022.778419.
  • Mauna JC, Harris SS, Pino JA, Edwards CM, DeChellis-Marks MR, Bassi CD, Garcia-Olivares J, Amara SH, Guajardo FG, Sotomayor-Zarate R, Terminel M, Castañeda E, Vetara M, Basut T, Thiels E, Torres GE. G protein subunits play a critical role in the actions of amphetamine. Transl Psychiatry. 2019 Feb 11;9(1):81.doi: 10.1038/s41398-019-0387-8.
  • Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle BT, Portz B, Pyles NJ, Guo L, Calder CB, Wills ZP, Pandey UB, Kofler JK, Brodsky JL, Thathiah A, Shorter J, Donnelly CJ. RNA-binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019 Feb 27;102:2 doi: 10.1016/j.neuron.2019.01048.
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel